Repligen's Q4 Slightly Tops Expectations
The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.
Repligen (NASDAQ:RGEN), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year. Revenue of $168 million, meanwhile, came in modestly above expectations of $167 million and up from $167 million in the prior-year period. However, its GAAP gross margin declined significantly to 23.2% from 47.1% a year prior.
Source: Analyst estimates for the quarter provided by FactSet.
Repligen is a leader in the development and production of innovative technologies used in the manufacturing of biological drugs, including therapeutic antibodies, vaccines, and cell and gene therapies.
